VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OSCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OSCROscar Health, Inc.
$29.84$7.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksOSCRCash Flow

Oscar Health, Inc. (OSCR) Cash Flow Statement

7Y historyFree accessUpdated daily

Operating cash flow swung from $2.6B in 2026Q1 to negative $1.2B in 2026Q3, with $1.6B of investment sales partly bridging the outflow, suggesting cash conversion remains unstable.

Income StatementBalance SheetCash FlowRatios

OSCR Cash Flow Statement

Annual statement

OSCR Cash Flow Statement

Oscar Health, Inc. (OSCR) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations4.14B1.09B978.19M-272.16M380.35M-181.75M222.73M-165.37M
Operating CF Growth %569.55%11.93%459.42%-171.56%309.28%-181.6%234.69%-
Operating CF / Revenue %23.68%9.36%10.66%-4.64%9.22%-9.46%37.77%-29.86%
Net Income855.5M-442.9M26.12M-270.59M-609.55M-571.43M-406.82M-261.18M
Depreciation & Amortization27.47M28.89M32.15M30.69M15.28M14.61M11.29M6.9M
Stock-Based Compensation77M87.65M109.82M159.68M112.33M86.3M35.87M33.56M
Deferred Taxes-1.69M2.45M-2.34M58K-165K-101K-67K-426K
Other Non-Cash Items3.59B-40.24M-26.42M86K7.46M41.19M6.77M-6.43M
Working Capital Changes-413.95M1.46B838.86M-192.09M855M247.7M575.7M62.21M
Cash from Investing-1.89B-241.06M-1.39B577.19M-226.52M-774.51M-344.71M150.51M
Capital Expenditures-40.93M-36.37M-27.9M-25.58M-29.01M-25.89M-14.02M-26M
Acquisitions000007.23M00
Purchase of Investments-5.18B-1.01B-2.13B-836.98M-1.19B-1.81B-1B-877.67M
Sale/Maturity of Investments3.32B804.96M770.04M1.44B994.08M1.05B671.59M1.06B
Other Investing1.26M4.28M3.93M-2.28M1.12M-555K-1.24M-7.08M
Cash from Financing27.58M399.21M68.39M6.45M301.11M1.24B611.71M-2.12M
Dividends Paid00000000
Share Repurchases0000000-2.99M
Stock Issued24.77M55.03M68.39M3.96M1.3M1.35B00
Debt Issuance (Net)-1000K1000K001000K-1000K1000K0
Other Financing7.49M-4.04M02.49M-5.19M43.56M89.04M873K
Net Change in Cash2.26B1.25B-340.85M311.47M454.94M282.45M489.73M-16.98M
Exchange Rate Effect-6.08M0000000
Cash at Beginning4.1B1.55B1.89B1.58B1.13B843.11M353.38M370.36M
Cash at End4.49B2.8B1.55B1.89B1.58B1.13B843.11M353.38M
Free Cash Flow4.1B1.06B950.3M-297.74M351.34M-207.63M208.71M-191.37M
FCF Growth %456.88%11.38%419.17%-184.74%269.21%-199.48%209.06%-
FCF Margin %23.45%9.05%10.35%-5.08%8.52%-10.81%35.4%-34.56%
FCF per Share11.824.033.57-1.341.65-1.160.87-0.8

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile underwriting cash conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Float Swings Mask Underlying Cash Generation

Based on reported quarterly figures, Oscar's operating cash flow swung from $2.6B in 2026Q1 to negative $1.2B in 2026Q3, a range too wide to read as a stable premium-to-claims float pattern.

The oscillation suggests that timing of premium receipts relative to claims payments, along with risk adjustment settlements, is driving much of the cash variability rather than steady underwriting economics. Operating cash flow to net income ratios ranging from -7.18 to 9.16 further indicate that net income is a weak guide to cash generation in this period. Investors should monitor whether claims paid of $4.2B in 2026Q3 reflect seasonal utilization or a durable shift in medical cost trends.

Portfolio Liquidations Funding Operating Outflows

According to reported cash flow data, Oscar sold $1.6B of investments in 2026Q3 while purchasing none, suggesting the quarter's negative operating cash flow was partly bridged by portfolio liquidation.

Heavy net sales of investments in the most recent quarter, following substantial net purchases of $4.0B in 2026Q2, point to an active reallocation of the float rather than a passive holding pattern. This raises the question of whether the investment portfolio is being used as a liquidity buffer for claims timing. The pattern warrants further investigation into the duration profile of the remaining holdings.

Earnings Inflection Not Yet Cash-Confirmed

Based on EDBL-style reporting, Oscar's net income of $679.0M in 2026Q1 was accompanied by $2.6B in operating cash flow, but 2026Q3 net income of $167.3M coincided with negative operating cash flow of $1.2B.

The divergence between reported profit and operating cash in the latest quarter may indicate that accrual-based items such as reserve movements and risk adjustment receivables are absorbing cash. Profitability has not yet been consistently reflected in cash generation across the ten-quarter window. The stated earnings beat should therefore be weighed against cash conversion before drawing conclusions about sustainability.

Claims Outflows Rising Faster Than Premium Inflows

As reported in financial statements, Oscar's claims and loss payments climbed from $2.1B in 2024Q4 to $4.2B in 2026Q3, a rise that warrants comparison against premium growth to assess medical cost pressure.

Claims outflows roughly doubling over the period is consistent with the reported 72.1% year-over-year revenue growth, but without a matched premium series it is difficult to confirm whether the medical loss ratio is improving. Rising paid claims during membership expansion may indicate higher early-enrollee utilization or inflation in provider rates. Investors should monitor whether claim payment lags are lengthening, as this would affect the float available to fund operations.

Cash Data Gaps Limit Conclusions

Several quarters report zero dividends, buybacks, and some investment activity, and premium collection data is not separately disclosed, so parts of the cash picture remain data unavailable.

Where fields are blank or zero, this analysis treats them as data unavailable rather than inferring a cause. The absence of premium receivable and broker lag data prevents direct testing of premium conversion efficiency. Conclusions about float generation should therefore be treated as provisional until fuller cash flow disclosure is reviewed.

OSCR — Frequently Asked Questions

Quick answers to the most common questions about buying OSCR stock.

How much cash does Oscar Health, Inc. (OSCR) generate from operations?

Oscar Health, Inc. (OSCR) generated $1.09B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Oscar Health, Inc.'s free cash flow?

Oscar Health, Inc. (OSCR) generated $1.06B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Oscar Health, Inc.'s capital expenditure (CapEx)?

Oscar Health, Inc. (OSCR) spent $36.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.